Cargando…

T cell composition and polygenic multiple sclerosis risk: A population‐based study in children

BACKGROUND AND PURPOSE: Patients with multiple sclerosis (MS) have altered T cell function and composition. Common genetic risk variants for MS affect proteins that function in the immune system. It is currently unclear to what extent T cell composition is affected by genetic risk factors for MS, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Mol, Casper L., Looman, Kirsten I. M., van Luijn, Marvin M., Kreft, Karim L., Jansen, Philip R., van Zelm, Menno C., Smolders, Joost J. F. M., White, Tonya J. H., Moll, Henriette A., Neuteboom, Rinze F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Multiple Sclerosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596816/ https://www.ncbi.nlm.nih.gov/pubmed/34251726 http://dx.doi.org/10.1111/ene.15019

Ejemplares similares

Multiple sclerosis risk variants influence the peripheral B‐cell compartment early in life in the general population
por: de Mol, Casper L., et al.
Publicado: (2022)

Prognostic value of natural killer cell/T cell ratios for disease activity in multiple sclerosis
por: Mimpen, Max, et al.
Publicado: (2020)

High consumption of coffee is associated with decreased multiple sclerosis risk; results from two independent studies
por: Hedström, A K, et al.
Publicado: (2016)

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT
por: Edan, G, et al.
Publicado: (2014)

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
por: Patti, F, et al.
Publicado: (2016)

A model for interrogating the clinico‐radiological paradox in multiple sclerosis: Internuclear ophthalmoplegia
por: Nij Bijvank, Jenny A., et al.
Publicado: (2021)

Adverse events related to biologicals used for patients with multiple sclerosis: a comparison between information originating from regulators and information originating from the scientific community
por: Minnema, L. A., et al.
Publicado: (2020)

Epstein–Barr virus infection after adolescence and human herpesvirus 6A as risk factors for multiple sclerosis
por: Biström, M., et al.
Publicado: (2020)

Re-evaluating the treatment of acute optic neuritis
por: Bennett, Jeffrey L, et al.
Publicado: (2015)

DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime?
por: van de Pavert, Steven H P, et al.
Publicado: (2016)

Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes
por: Colato, Elisa, et al.
Publicado: (2021)

Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study
por: Arnold, Douglas L, et al.
Publicado: (2020)

Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial
por: Vermersch, Patrick, et al.
Publicado: (2021)

Memory in multiple sclerosis is linked to glutamate concentration in grey matter regions
por: Muhlert, Nils, et al.
Publicado: (2014)

Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes
por: De Stefano, Nicola, et al.
Publicado: (2014)

A 60-year follow-up of the incidence and prevalence of multiple sclerosis in Hordaland County, Western Norway
por: Grytten, N, et al.
Publicado: (2016)

Smartphone‐derived keystroke dynamics are sensitive to relevant changes in multiple sclerosis
por: Lam, Ka‐Hoo, et al.
Publicado: (2021)

Stressful life events are associated with the risk of multiple sclerosis
por: Jiang, X., et al.
Publicado: (2020)

Retinal inter-eye difference and atrophy progression in multiple sclerosis diagnostics
por: Nij Bijvank, Jenny, et al.
Publicado: (2022)

Brain age as a surrogate marker for cognitive performance in multiple sclerosis
por: Denissen, Stijn, et al.
Publicado: (2022)

Imaging outcomes for trials of remyelination in multiple sclerosis
por: Mallik, Shahrukh, et al.
Publicado: (2014)

Incidence and prevalence of multiple sclerosis in the UK 1990–2010: a descriptive study in the General Practice Research Database
por: Mackenzie, I S, et al.
Publicado: (2014)

Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Automated brain volumetrics in multiple sclerosis: a step closer to clinical application
por: Wang, C, et al.
Publicado: (2016)

Confirmed disability progression as a marker of permanent disability in multiple sclerosis
por: Sharmin, Sifat, et al.
Publicado: (2022)

Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?
por: Cerqueira, João J, et al.
Publicado: (2018)

Association of adverse childhood experiences with the development of multiple sclerosis
por: Eid, Karine, et al.
Publicado: (2022)

Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials
por: Harris, Sarah, et al.
Publicado: (2021)

Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron
por: Haider, Lukas, et al.
Publicado: (2014)

The grey matter correlates of impaired decision-making in multiple sclerosis
por: Muhlert, Nils, et al.
Publicado: (2015)

Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15
por: Kappos, Ludwig, et al.
Publicado: (2015)

Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group
por: McGuigan, C, et al.
Publicado: (2016)

Structural network disruption markers explain disability in multiple sclerosis
por: Charalambous, Thalis, et al.
Publicado: (2019)

Central nervous system atrophy predicts future dynamics of disability progression in a real‐world multiple sclerosis cohort
por: Tsagkas, Charidimos, et al.
Publicado: (2021)

Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study
por: Lie, Ingrid Anne, et al.
Publicado: (2022)

MRI in Leber's hereditary optic neuropathy: the relationship to multiple sclerosis
por: Matthews, Lucy, et al.
Publicado: (2015)

Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta‐1a
por: Battaglini, Marco, et al.
Publicado: (2022)

Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry
por: Butzkueven, Helmut, et al.
Publicado: (2021)

Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab
por: Räuber, Saskia, et al.
Publicado: (2022)

Tobacco smoking and excess mortality in multiple sclerosis: a cohort study
por: Manouchehrinia, Ali, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_q84jn3ean9fggo0cdvcegs0dv7